ReviewThe journal of prevention of Alzheimer's disease
Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review.
Review in The journal of prevention of Alzheimer's disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Review of Dementia Caregiver Interventions: Valuing Psychological Well-Being and Economic Impact Through the State-Preference Method.International journal of environmental research and public health · 2026Pooled it
- Gender differences in informal caregiving costs and burden in Alzheimer disease: a multinational cross-sectional analysis.BMC public health · 2026Article
- Associations of Alzheimer's disease with inpatient hospital costs and with quality-adjusted life years: evidence from conventional and Mendelian randomization analyses in the UK Biobank.Cost effectiveness and resource allocation : C/E · 2025Article
- Global Societal Burden of Alzheimer's Disease by Severity: a Targeted Literature Review.Neurology and therapy · 2025Review
- Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Time value of informal care of people with alzheimer's disease in Spain: a population-based analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Annual societal cost of Alzheimer's disease in Malaysia: a micro-costing approach.BMC geriatrics · 2025Article
- Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.Journal of Alzheimer's disease : JAD · 2024Article
- Exploring the relationship between patient-relevant outcomes and Alzheimer's disease progression assessed using the clinical dementia rating scale: a systematic literature review.Frontiers in neurology · 2023Review
- Mediation Analysis and Mixed-Effects Models for the Identification of Stage-specific Imaging Genetics Patterns in Alzheimer's Disease.Proceedings. IEEE International Conference on Bioinformatics and Biomedicine · 2022Article
- Article
- Protective effect of irisin against Alzheimer's disease.Frontiers in psychiatry · 2022Review
- Contribution of Iranian researchers in Alzheimer's disease research: A 10 years scientometric analysis.Journal of diabetes and metabolic disorders · 2021Review
- Multilevel prediction of Alzheimer's disease dementia in the United States: An artificial intelligence analysis.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's Disease is the most common cause of dementia, affecting memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. AD is predicted to increase healthcare spending and costs associated with formal and informal caregiving. The aim of this study was to identify and quantify the contribution of the different cost components associated with AD.
methodsA structured literature review was conducted to identify studies reporting the economic burden of Alzheimer`s Disease beyond the healthcare setting. The search was conducted in Medline, Embase and EconLit and limited to studies published in the last 10 years. For each identified cost component, frequency weighted mean costs were calculated across countries to estimate the percentage contribution of each component by care setting and disease severity. Results obtained by each costing approach were also compared.
resultsFor community-dwelling adults, the percentage of healthcare, social care and indirect costs to total costs were 13.9%, 17.4% and 68.7%, respectively. The percentage of costs varied by disease severity with 26.0% and 10.4% of costs spent on healthcare for mild and severe disease, respectively. The proportion of total spending on indirect costs changed from 60.7% to 72.5% as disease progressed. For those in residential care, the contribution of each cost component was similar between moderate and severe disease. Social care accounted on average for 85.9% of total costs.
conclusionThe contribution of healthcare costs to the overall burden was not negligible; but was generally exceeded by social and informal care costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.